Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R²) Across Relapsed or Refractory (R/R
Go back to Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R²) Across Relapsed or Refractory (R/R| (NASDAQ: GMAB) | Delayed: 25.60 +0.33 (1.31%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.27 | 52 Week High | $ | |||
| Open | $25.05 | 52 Week Low | $ | |||
| Day High | $25.66 | P/E | N/A | |||
| Day Low | $25.16 | EPS | $ | |||
| Volume | 1,479,380 | |||||
